^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Tubulin polymerization promoter

    Related drugs:
    2d
    CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. (PubMed, Cancer Res Commun)
    Post-carboplatin analysis revealed increased CLDN6 expression, EMT-related gene changes, and enhanced T-cell infiltration, which were associated with the synergistic effect of SAIL66. Our study provides insights into the biology and plasticity of CLDN6-positive cells in EOC heterogeneity and highlights the clinical significance of CLDN6-targeting therapies for ovarian cancer treatment.
    Journal • IO biomarker
    |
    CLDN6 (Claudin 6)
    |
    carboplatin • SAIL66
    2d
    Impact of Immunohistochemical PSA and Ki-67 Expression on Prognosis in Metastatic Castration-Sensitive Prostate Cancer. (PubMed, Int J Urol)
    Immunohistochemical PSA and Ki-67 expression provide practical prognostic information for patients with metastatic castration-sensitive prostate cancer. Combined assessment with EOD ≥ 3 identifies a high-risk subgroup with unfavorable clinical outcomes.
    Clinical • Retrospective data • Journal
    |
    KLK3 (Kallikrein-related peptidase 3)
    |
    docetaxel • Nubeqa (darolutamide)
    3d
    PBX1-mediated transcription of AP1M2 promotes triple-negative breast cancer malignant progression and docetaxel resistance. (PubMed, Gene)
    PBX1-mediated AP1M2 facilitates cell proliferation, migration, invasion, and docetaxel resistance to accelerate TNBC malignant behavior, providing a novel target for TNBC treatment.
    Journal
    |
    PBX1 (PBX Homeobox 1)
    |
    docetaxel
    4d
    Efficacy and safety of All-site Radiation therapy and Standard Of Care Therapy with or without Docetaxel for GG5 metastatic Prostate Cancer: A Ambispective Cohort Study (ChiCTR2500112793)
    P=N/A, N=520, Not yet recruiting, Peking University First Hospital; Peking University First Hospital
    New trial
    |
    docetaxel
    4d
    A study on the treatment of advanced gastric/gastroesophageal junction adenocarcinoma with docetaxel for injection (albumin-bound type) combined with oxaliplatin and 5-FU/LV (ADOF) (ChiCTR2500112147)
    P=N/A, N=12, Not yet recruiting, Fujian Cancer Hospital; CSPC Zhongqi Pharmaceutical Technology Co., Ltd.
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR • HER-2 overexpression
    |
    5-fluorouracil • oxaliplatin • albumin-bound docetaxel (CPO100)
    4d
    Efficacy and Safety of Epalolitovorellizumab in Combination with Docetaxel in Advanced Non-Small-Cell Lung Cancer Progressing After First-Line Immunotherapy (ChiCTR2500112069)
    P=N/A, N=33, Not yet recruiting, Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    docetaxel
    4d
    A single-arm exploratory clinical trial of Utidelone injection for advanced pancreatic cancer refractory to standard therapy (ChiCTR2500112307)
    P=N/A, N=48, Recruiting, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    New trial
    |
    utidelone IV (UTD1)
    4d
    A clinical study of carboplatin/albumin paclitaxel combined with PD-L1 inhibitor as neoadjuvant therapy for resectable Cervical Esophageal Squamous Cell Carcinoma (ChiCTR2500114965)
    P2, N=30, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • albumin-bound paclitaxel • Hetronifly (serplulimab)
    4d
    Study on the efficacy of Utidelone combined with Anotinib in the treatment of advanced Non-Small Cell Lung Cancer (ChiCTR2500115269)
    P2, N=61, Not yet recruiting, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen Un
    New P2 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK fusion
    |
    Focus V (anlotinib) • utidelone IV (UTD1)
    6d
    SWOG S2210: Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation (clinicaltrials.gov)
    P2, N=44, Recruiting, SWOG Cancer Research Network | Trial primary completion date: Jul 2029 --> Jul 2027
    Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    carboplatin
    6d
    Characterization and validation of a bone metastatic castration-resistant prostate cancer model as a nanomedicine evaluation platform. (PubMed, Theranostics)
    Poor solubility, systemic toxicity, and therapeutic resistance hamper conventional approaches, such as docetaxel (Dtx) treatment... Our intratibial bone mCRPC mouse model provides a robust platform for studying PCa bone metastases and evaluating nanomedicine efficacy. PGA-Dtx displays promise as a safe and effective therapy for mCRPC, offering improved drug delivery and reduced systemic side effects, which supports the translational potential of polymer-drug conjugates in mCRPC management.
    Preclinical • Journal
    |
    CTSK (Cathepsin K)
    |
    docetaxel
    6d
    Ferritin as a novel predictive index for nasopharyngeal carcinoma survival and therapeutic efficacy of different chemotherapy regimens. (PubMed, World J Clin Oncol)
    The chemotherapy regimens of NF, TN, and TP for NPC are associated with the prognosis of NPC. The Ferritin index is an important indicator for predicting NPC survival.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    cisplatin • docetaxel • 5-fluorouracil